TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Conditions: Squamous Cell Carcinoma of Head and Neck; Metastatic Squamous Cell Carcinoma Interventions: Biological: TBio-4101; Drug: Pembrolizumab; Drug: Platinum based chemotherapy; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Aldesleukin Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Turnstone Biologics, Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
Aerobic Dance During Chemotherapy in Breast Cancer Patients With Cognitive Impairment
Conditions: Breast Neoplasms; Exercise Therapy; Chemotherapy-Related Cognitive Impairment; Cognitive Dysfunction; Dance Therapy Interventions: Other: Aerobic dance; Other: Fast-walking Sponsors: The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer
Conditions: Oropharynx Cancer; HPV-Related Carcinoma Interventions: Radiation: Radiation; Drug: Platinum based chemotherapy Sponsors: University of Michigan Rogel Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test
Conditions: Acute Myeloid Leukemia in Children Interventions: Other: Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test Sponsors: The Children ' s Hospital of Zhejiang University School of Medicine; Zhejiang University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP)
Conditions: Lung Cancer, Nonsmall Cell; Esophageal Carcinoma Interventions: Drug: Camrelizumab; Drug: Thalidomide 50mg; Drug: Thalidomide 100mg; Drug: Thalidomide 200mg; Drug: Chemotherapy Sponsors: Henan Cancer Hospital; First Affiliated Hospital Xi ' an Jiaotong University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
An Open Prospective Randomized Clinical Study of the Effectiveness, Tolerability and Safety of a Single Intraperitoneal Use of the Drug " Prospidelong, Powder for the Preparation of a Gel for Topical Use, 1000 mg in Vials, Package No. 1 " in Patients With Disseminated Gastric Cancer, Phase I-II
Conditions: Gastric Cancer With Peritoneal Dissemination Interventions: Drug: Prospidelong; Procedure: chemotherapy Sponsors: Research Institute for Physical Chemical Problems of the Belarusian State University; The state institution N. N. Alexandrov National Cancer Centre of Belarus; Unitary Enterprise UNITEHPROM BSU Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
A Study of Etoposide-carboplatin in Combination With Pembrolizumab and Lenvatinib Maintenance in HG-NETs
Conditions: Neuroendocrine Tumors Interventions: Combination Product: Pembrolizumab in combination with carboplatin and etoposide chemotherapy followed by pembrolizumab and lenvatinib maintenance therapy Sponsors: Imperial College London Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
Conditions: Metastatic Colorectal Cancer Interventions: Drug: Adebrelimab + Cetuximab+ Chemotherapy Sponsors: The First Affiliated Hospital of Zhengzhou University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Conditions: Biliary Tract Neoplasms Immunotherapy Interventions: Drug: Pembrolizumab,Lenvatinib and Gemox Chemotherapy （Gemcitabine and Oxaliplatin）; Drug: Pembrolizumab and Lenvatinib; Drug: Pembrolizumab and Gemox Chemotherapy（Gemcitabine and Oxaliplatin） Sponsors: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 30, 2024 Category: Research Source Type: clinical trials
FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech ’s NT-I7 for Advanced Pancreatic Cancer Treatment
January 30, 2024— ROCKVILLE, MD --- Pancreatic cancer has the highest mortality rate of all major cancers with only a 3% relative-survival-rate at 5-years for the advanced form.[i], [ii]- Pancreatic tumors are highly resistant to chemotherapy... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 30, 2024 Category: Pharmaceuticals Source Type: clinical trials
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
Conditions: Her-2 Negative Breast Cancer With Leptomeningeal Metastasis Interventions: Device: Ommaya reservoir; Drug: Systematic chemotherapy Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
Conditions: Recurrent Nasopharyngeal Carcinoma Interventions: Drug: Immunotherapy,Toripalimab Injection; Drug: Chemotherapy,Gemcitabine based regimen Sponsors: Eye& ENT Hospital of Fudan University; Shanghai Zhongshan Hospital; Shanghai 6th People ' s Hospital; Changhai Hospital; Fujian Medical University Union Hospital; People ' s Hospital of Guangxi; Shenzhen Second People ' s Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer
Conditions: Colorectal Neoplasms; Chemotherapy Effect; Molecular Sequence Variation Interventions: Drug: Cetuximab Sponsors: City Clinical Oncology Hospital No 1; Atlas Biomed; N.N. Blokhin National Medical Research Center of Oncology; Moscow MultidisciplinaryClinical Center Kommunarka Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Study of DV Plus Toripalimab in Combination or Sequence With Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Conditions: Breast Cancer Interventions: Drug: Disitamab Vedotin Injection （18 weeks）; Drug: Toripalimab （18weeks）; Drug: Carboplatin; Drug: Disitamab Vedotin Injection （12 weeks）; Drug: Sequential Epirubicin; Drug: Sequential CTX; Drug: Toripalimab （12weeks） Sponsors: RemeGen Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
Conditions: Acute Myeloid Leukemias Interventions: Drug: SNDX-5613; Drug: Chemotherapy Regimen; Drug: HiDAC Sponsors: Syndax Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
